Pharmacokinetic stereoselectivity of troglitazone, an antidiabetic agent, in the KK mouse

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 4, 1997, Pages 305-324

  Izumi, T ^a   Enomoto, S ^a   Hoshiyama, K ^a   Sasahara, K ^a   Sugiyama, Y ^b  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

epimerization; pharmacokinetics; stereoselectivity; troglitazone

Indexed keywords

ANTIDIABETIC AGENT; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG STRUCTURE; DRUG TISSUE LEVEL; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOKINETICS; STEREOISOMERISM; STEREOSPECIFICITY;

ANIMALS; BLOOD PROTEINS; CHROMANS; HYPOGLYCEMIC AGENTS; INTESTINES; KIDNEY; LIVER; MALE; MICE; MICE, INBRED STRAINS; STEREOISOMERISM; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031006317     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199705)18:4<305::AID-BDD19>3.0.CO;2-L     Document Type: Article

References (26)

1. K. Williams and E. Lee, Importance of drug enantiomers in clinical pharmacology. Drugs, 30, 333-354 (1985).
2. Y. W. F. Lam, Stereoselectivity: an issue of significant importance in clinical pharmacology. Pharmacotherapy, 8, 147-157 (1988).
3. F. Jamali, R. Mehvar and F. M. Pasutto, Enantioselective aspects of drug action and disposition: Therapeutic Pitfalls. J. Pharm. Sci., 78, 695-715 (1989).
4. D. B. Campbell, Stereoselectivity in clinical pharmacokinetics and drug development. Eur. J. Drug Metab. Pharmacokinet., 35, 109-125 (1990).
5. G. R. Wilkinson, Clearance approaches in Pharmacology. Pharmacol. Rev., 39, 1-47 (1987).
6. M. Rowland and T. N. Tozer, Clinical Pharmacokinetics: Concepts and Applications. Lea and Febiger, 1980
7. W. F. Trager and J. P. Jones, Stereochemical consideration in drug metabolism. Prog. Drug Metab., 10, 55-83 (1987).
8. J. Caldwell, A. J. Hutt and F. G. Fournel, The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem. Pharmacol., 37, 105-114 (1988).
9. Y. Aso, S. Yoshioka and Y. Takeda, Epimerization and racemization of some chiral drugs in the presence of human serum albumin. Chem. Pharm. Bull., 38, 180-184 (1990).
10. T. Yokoyama, K. Fukuda, S. Mori, M. Ogawa and K. Nasagawa, Determination of tolperisone enantiomers in plasma and their disposition in rats. Chem. Pharm. Bull., 40, 272-274 (1992).
11. J. Shimada, S. Hori, T. Oguma, T. Yoshikawa, S. Yamamoto, T. Nishikawa and H. Yamada, Effects of protein binding on the isomerization of ceftibuten. J. Pharm. Sci., 82, 461-465 (1993).
12. B. Knoche and G. Blaschke, Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography. J. Chromatogr., 666, 235-240 (1994).
13. T. Fujiwara, S. Yoshioka, T. Yoshioka, I. Ushiyama and H. Horikoshi, Characterization of new antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes, 37, 1549-1558 (1988).
14. T. Fujiwara, M. Wada, K. Fukuda, M. Fukami, S. Yoshioka, T. Yoshida and H. Horikoshi, Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57 BL/KsJ-db/db mice. Metabolism, 40, 1213-1218 (1991).
15. J. Suter, J. Nolan, P. Wallace, B. Bumbiner and J. M. Olefsky, Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care, 15, 193-203 (1992).
16. A. Shibukawa, T. Sawada, N. Nishimura, M. Miyake and H. Tanaka, Determination of free drug in protein binding equilibrium by high-performance frontal analysis using internal-surface reversed-phase support. Chem. Pharm. Bull., 37, 702-706 (1989).
17. A. Shibukawa, C. Nakao, T. Sawada, N. Morokoshi and T. Nakagawa, Determination of unbound concentration of hydrophobic drugs in albumin solution by high-performance frontal analysis using a diol-silica column. J. Pharm. Sci., 83, 868-876 (1994).
18. A. Shibukawa, T. Sawada, C. Nakao, T. Izumi and T. Nakagawa, High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and human plasma. J. Chromatogr. A, 697, 337-347 (1995).
19. T. Izumi, S. Enomoto, K. Hoshiyama, K. Sasahara, A. Shibukawa, T. Nakagawa and Y. Sugiyama, Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, using an animal scale-up approach. J. Pharm. Exp. Ther., in press.
20. B. Davies and T. Morris, Physiological parameters in laboratory animals and humans. Pharm. Res., 10, 1093-1095 (1993).
21. T. Sohda, K. Mizuno and Y. Kawamatsu, Studies on antidiabetic agents. VI. Asymmetric transformation of (±)-4-[4-(1-methyl cyclohexylmethoxy)benzyl]-2,4-thiazolidinedione (ciglitazone) with optically active 1-phenylethylamines. Chem. Pharm. Bull., 32, 4460-4465 (1984).
22. D. A. Clark, S. W. Goldstein, R. A. Volkmann, J. E. Eggler, G. F. Holland, B. Huhn, R. W. Stevenson, D. K. Kreutter, M. Gibbs, M. N. Krupp, P. Merrigan, P. L. Kelbaugh, W. H. Kappeler, R. E. Mcdermott, N. J. Hutson and M. R. Johnson, Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4, -diones and hypoglycemic agents. J. Med. Chem., 34, 319-325 (1991).
23. P. P. Minghetti, S. W. Law and A. Dugaiczk, The rate of molecular evolution of a-fetoprotein approaches that of pseudogenes. Mol. Biol. Evol., 2, 347-348 (1985).
24. T. Izumi, K. Hoshiyama, K. Sasahara and Y. Sugiyama, Determination of protein binding of troglitazone stereoisomers by fluorometric titration. Biopharm. Drug Disposit., submitted.
25. H. Cheng and W. J. Jusko, Pharmacokinetics of reversible metabolic systems. Biopharm. Drug Disposit., 14, 721-766 (1993).
26. W. F. Ebling and W. J. Jusko, The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits. J. Pharmacokinet. Biopharm., 14, 577-590 (1986).